Psyence Biomed Launches First Trial Site In Australia For Phase IIb Psilocybin Study In Palliative Care
Portfolio Pulse from Juan Spínelli
Psyence Biomedical Ltd. (NASDAQ:PBM) has launched its first clinical trial site in Australia for a Phase IIb study on psilocybin as a treatment for Adjustment Disorder in palliative care patients. This marks a significant step in advancing psychedelic-based treatments, with patient screening starting immediately and data expected by 2025.
September 09, 2024 | 10:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Psyence Biomedical Ltd. has initiated its first clinical trial site in Australia for a Phase IIb study on psilocybin, marking a significant milestone in psychedelic-based treatments. This development could lead to a pivotal Phase III program.
The initiation of the trial site in Australia is a major milestone for Psyence Biomedical, indicating progress in their psychedelic-based treatment research. This could positively impact the company's stock as it moves closer to a potential Phase III program.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100